Translation of "Peripheral artery disease" in German

Outside the coronary arteries, percutaneous transluminal angioplasty is used primarily in the case of peripheral artery occlusion disease.

Iscover as an anticoagulant has been compared with aspirin in a study called CAPRIE including around 19,000 patients who had recently had a heart attack or an ischaemic stroke, or who had established peripheral artery disease.

Patients with high cardiovascular risk, history of peripheral artery disease and/or of connective tissue disorders and/or interstitial lung disease were excluded from the study.

Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

Your doctor will tell you when to start treatment with Xarelto if you have been diagnosed with coronary artery disease or peripheral artery disease.

In a case of occlusive peripheral and coronary artery disease, the remedy Bismuth subsalicylicum combines the destructive stage 15 of the Gold series, related to the heart and circulation, with the blood-thinning quality of salicylic acid.

When this occurs in the arms or legs, it is known as peripheral artery disease (PAD).

As peripheral arterial disease and secondary amyloidosis account for significant morbidity among end-stage renal disease patients, we performed a prospective study regarding the impact of ozonotherapy on peripheral artery disease and bone pain in hemodialysis patients.

For example, just over a month ago we received marketing authorization for Xarelto in the United States in another indication: treatment of coronary artery disease and peripheral artery disease, a condition where the blood flow to the legs is reduced.

For example, this year we might receive marketing authorization in Europe and the United States for the use of XareltoTM in a further indication: the treatment of coronary heart disease and peripheral artery disease, also known as intermittent claudication.

About CLI In the US alone, it is estimated that 8-12 million people suffer from Critical Limb Ischemia (CLI) associated with Peripheral Artery Disease (PAD).

Patients suffering from cardiac or peripheral vascular diseases (i.e. acute heart attack, chronic ischemic heart disease and peripheral artery disease) can have stem cells taken from their hip bone.

Another subject matter of the present invention relates to the use of the fusion protein according to the invention and/or the homodimer according to the invention and/or the protein acid molecule according to the invention for the production of a pharmaceutical and/or diagnostic composition for the treatment and/or diagnosis of acute or chronic vascular diseases, including atherosclerosis, atherosclerotic plaques, cardiac infarction, apoplexy and peripheral artery occlusive disease (PAOD).

Atherosclerosis-associated diseases, including in particular stroke, coronary heart disease (CHD) and peripheral artery occlusive disease, affect people in industrial countries to a considerable extent.

In the peripheral vascular area, a phase I/II proof-of-concept study was completed in the indication peripheral artery disease, including PAOD and thromboangiitis obliterans patients.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from critical limb ischemia (CLI), an end stage of peripheral artery disease (PAD).

In addition to the already approved indications, the use of rivaroxaban is also being investigated in other cardiovascular diseases such as prevention of major adverse cardiac events, embolic stroke of undetermined source or peripheral artery disease.

With the combined treatment approach of rivaroxaban and AspirinTM, the risk of stroke in patients with chronic coronary or peripheral artery disease was reduced by 42% and the risk of cardiovascular death by 22%.

Causes of gangrene include diabetes, atherosclerosis of the limbs, peripheral artery disease, smoking, trauma, obesity, and Raynaud's Disease.

In February 2017, the Phase III COMPASS study with Bayer's rivaroxaban in patients with coronary or peripheral artery disease showed overwhelming efficacy and met its primary endpoint early.

Cardiovascular Systems, Inc., based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating peripheral and coronary artery disease (PAD and CAD).

Before taking Betapace you should talk with your doctor if you have severe or prolonged diarrhea or vomiting, low electrolytes (low potassium levels), long QT syndrome, peripheral artery disease, kidney disease, kidney failure, diabetes, chest pain (angina), heart failure, sick sinus syndrome, slow heart rate (bradycardia), asthma, chronic obstructive pulmonary disease, overactive thyroid disease (hyperthyroidism), upcoming surgery, any allergies.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD).

State-of-the-art therapeutic and surgical methods are also available for all other important vascular diseases such as peripheral artery occlusive disease (PAOD) and vascular occlusions of the extremities or carotid arteries.